A model for the classification of 70 HIV-1 protease crystal structure binding pockets to one of its complexed FDA approved protease inhibitors utilizing Random Forest has been developed. 456 chemical descriptors of the binding pocket of each crystal structure have been computed and are used to develop the classification model. Simulations were performed to determine the optimal Random Forest mo...

Recently, we cloned a human organic cation transporter, hOCT1, which is expressed primarily in the liver. hOCT1 plays an important role in the cellular uptake and elimination of various xenobiotics including therapeutically important drugs. HIV protease inhibitors are a new class of therapeutic agents. The purpose of this study was to elucidate the interactions of HIV protease inhibitors with h...

Human immunodeficiency virus infection / acquired immunodeficiency syndrome (HIV/AIDS) is a disease pertained to the human immune system. Given its crucial role in viral replication, HIV-1 protease (HIV-1 PR) is a prime therapeutic target in AIDS therapy. In this regard, the dynamic aspects of ligand-enzyme interactions may indicate an important role of conformational variability in HIV-1 PR in...

The human immunodeficiency virus (HIV) protease is a homodimeric aspartyl protease that is crucial for the viral life-cycle, cleaving proviral polyproteins, hence creating mature protein components that are required for the formation of an infectious virus. With diagnostic measures and clinically used protease inhibitors focusing on HIV-1, due to its higher virulence and prevalence, studies of ...

BACKGROUND As a drug target and an antigenic agent, HIV-1 protease (HIV-1 PR) is at the center of attention for designing anti-AIDS inhibitors and diagnostic tests. In previous studies, the production of the recombinant protease has been faced with several difficulties; therefore, the aims of this study were the easy production, purification of the soluble form of protease in E. coli and invest...

BACKGROUND Tests for resistance to HIV drugs are available for clinical use; however, their predictive value has not been fully assessed. OBJECTIVES To determine HIV-1 genotypic predictors of a virologic response to saquinavir-ritonavir therapy in patients in whom at least one previous protease inhibitor-containing regimen had failed and to compare the predictive value of baseline genotype wi...

UNLABELLED Resistance to various human immunodeficiency virus type 1 (HIV-1) protease inhibitors (PIs) challenges the effectiveness of therapies in treating HIV-1-infected individuals and AIDS patients. The virus accumulates mutations within the protease (PR) that render the PIs less potent. Occasionally, Gag sequences also coevolve with mutations at PR cleavage sites contributing to drug resis...

Correction for ‘Heterocycle-derived organosilatranes as naked eye sensors Sn 2+ ions and their potential inhibiting activity against HIV-1 protease via a computational approach’ by Gurjaspreet Singh et al. , New J. Chem. 2023, 47 12608–12619, https://doi.org/10.1039/d3nj01484c.

phytochemical investigation of the aerial parts of euphorbia erythradenia bioss. (euphorbiaceae), one of iranian endemic euphorbias, with particular attention to triterpene constituents, using methanol solvent extraction was carried out. five known triterpenes, including four cycloartanes and oleanolic acid, were isolated for the first time and identified using nmr and mass techniques. anti hiv...

Recombinant human immunodeficiency virus 1 (HIV-1) protease, purified from a bacterial expression system, processed a recombinant form of its natural substrate, Pr55gag, into protein fragments that possess molecular weights commensurate with those of the virion gag proteins. Molecular weights of the protease obtained under denaturing and nondenaturing conditions (11,000 and 22,000, respectively...